|
CWDHP
|
Alkaline pretreatment (°C)
|
Concentration in CWDHP or alkali-insoluble residues (%)
|
|---|
| | |
Lignin
|
Glucose
|
Xylose
|
Arabinose
|
Galactose
|
|---|
|
Control
|
None
|
20.2aa
|
29.6 g
|
x11.5b
|
16.2b
|
7.3bc
|
| |
70
|
16.2b
|
32.0f
|
11.4b
|
16.5b
|
8.0a
|
| |
100
|
17.6b
|
34.0e
|
11.4 b
|
16.5b
|
7.1d
|
| |
130
|
16.9b
|
35.9d
|
12.9a
|
18.3a
|
5.6e
|
|
EGCG
|
None
|
18.4ab
|
30.4 fg
|
11.5b
|
16.0b
|
7.4b
|
| |
70
|
8.9c
|
40.9c
|
11.6b
|
14.9 c
|
7.1 cd
|
| |
100
|
6.5d
|
43.5b
|
9.9c
|
12.3d
|
7.2 cd
|
| |
130
|
5.5d
|
48.8a
|
9.7c
|
10.8e
|
4.4f
|
|
Analysis of variance
| | | | | |
|
CWDHP
|
†
|
***
|
***
|
***
|
***
|
|
Pretreatment
|
***
|
***
|
**
|
**
|
***
|
|
CWDHP X Pretreatment Interaction
|
***
|
***
|
***
|
***
|
***
|
- The CWDHP were formed with monolignols (control) or with monolignols plus epigallocatechin gallate (EGCG) and pretreated with 0.075 M sodium hydroxide (15% w/w loading) at various temperatures.
- a Means within columns with unlike letters differ (P < 0.05).
- † P < 0.1; * P < 0.05; ** P < 0.01, *** P < 0.001.
